These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 36371234)

  • 21. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
    Rodziewicz M; Dyball S; Lunt M; McDonald S; Sutton E; Parker B; Bruce IN;
    Lancet Rheumatol; 2023 May; 5(5):e284-e292. PubMed ID: 38251591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
    Ruiz-Irastorza G; Danza A; Khamashta M
    Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belimumab for systemic lupus erythematosus.
    Singh JA; Shah NP; Mudano AS
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents.
    Wise LM; Stohl W
    Front Med (Lausanne); 2020; 7():303. PubMed ID: 32695790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis.
    Shamliyan TA; Dospinescu P
    Clin Ther; 2017 Jul; 39(7):1479-1506.e45. PubMed ID: 28673504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
    Atisha-Fregoso Y; Malkiel S; Harris KM; Byron M; Ding L; Kanaparthi S; Barry WT; Gao W; Ryker K; Tosta P; Askanase AD; Boackle SA; Chatham WW; Kamen DL; Karp DR; Kirou KA; Sam Lim S; Marder B; McMahon M; Parikh SV; Pendergraft WF; Podoll AS; Saxena A; Wofsy D; Diamond B; Smilek DE; Aranow C; Dall'Era M
    Arthritis Rheumatol; 2021 Jan; 73(1):121-131. PubMed ID: 32755035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
    Urowitz MB; Aranow C; Asukai Y; Bass DL; Bruce IN; Chauhan D; Dall'Era M; Furie R; Fox NL; Gilbride JA; Hammer A; Ginzler EM; Gonzalez-Rivera T; Levy RA; Merrill JT; Quasny H; Roth DA; Stohl W; van Vollenhoven R; Wallace DJ; Petri M
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1822-1828. PubMed ID: 35439360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment with Belimumab in a Patient with Refractory Systemic Lupus Erythematosus after Initiation of Hemodialysis: Considering the Synergistic Effect of Belimumab and Immunological Burn-Out Phenomenon in End-Stage Renal Disease Patients on Hemodialysis.
    Karasawa K; Ogura S; Takabe T; Miyabe Y; Iwabuchi Y; Akiyama K; Sato M; Moriyama T; Uchida K; Nitta K
    Blood Purif; 2022; 51(2):182-188. PubMed ID: 33895749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
    Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
    Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
    Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
    Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 38. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B cell depletion and inhibition in systemic lupus erythematosus.
    Krustev E; Clarke AE; Barber MRW
    Expert Rev Clin Immunol; 2023 Jan; 19(1):55-70. PubMed ID: 36342225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.